The nation's long-time quest to boost its international standing in the biotechnology sector was partially rewarded last week with the government's announcement that it would invest US$20 million in a new biotech company that will focus on developing AIDS drugs, hepatitis vaccines and bird flu vaccines.
TaiMed Biologics Co is expected to bring a new AIDS drug, TNX-355, to the market in three years, which would make it the first drug to be produced and marketed globally by a Taiwanese company.
TNX-355 is a humanized monoclonal antibody that can prevent HIV from breaching immune system cells. It was first developed by the US pharmaceutical firm Tanox. Genentech acquired the patent following a merger earlier this year.
TaiMed Biologics secured authorization to use the patented antibody from Genentech and will conduct a second clinical trial of the drug later this year in the US, Europe and South America to evaluate its safety and efficacy.
At issue is an ambitious investment for a private biotech start-up that has obtained massive funding from the state-owned National Development Fund in return for a stake of 40 percent in the company, and which is planning to raise US$50 million in capital globally.
Nearly as remarkable as the investment itself is the company's management line-up, which includes former vice premier Tsai Ing-wen (
No one can say for sure whether TaiMed Biologics will be profitable, because companies that intend to market a new drug must go through a complex, time-consuming and very expensive process.
On a positive note, the legislative passage of the Biotech and New Pharmaceutical Development Act (
The issue facing the government and investors is how to position TaiMed Biologics and how they will view similar local firms, if the nation aims to gain international recognition in the biotech sector.
A high level of education, a good health care system and quality medical research give Taiwan an edge in biotech development, but the nation lacks good support from a well-developed investment environment where efficient bureaucracy, committed enterprises and a sufficient pool of legal and financial professionals are crucial and interdependent.
But a more important issue is how Taiwan sees itself in the biotech supply chain: Is it a research-oriented participant or a end-product manufacturer?
Should our biotech firms focus on buying rights to promising drugs developed overseas that have a potential to become profitable? Or should the sector focus on making compounds based on customers' designs -- the way Taiwan Semiconductor Manufacturing Co does in the chip industry or Quanta Computer in the PC industry.
This would be a short-term option that would give local companies the experience they need by studying partly developed products and conducting clinical trials on a contract basis.
But in the long run, for Taiwan to really gain international visibility, it must have local biotech companies that are capable of developing new compounds in local laboratories and taking them through the clinical trial and regulatory approval stages. That will be very expensive. Does the government -- or local industry -- really have the deep pockets or the determination necessary to see this happen?
After Chinese Nationalist Party (KMT) Chairwoman Cheng Li-wun (鄭麗文) met Chinese President Xi Jinping (習近平) in Beijing, most headlines referred to her as the leader of the opposition in Taiwan. Is she really, though? Being the chairwoman of the KMT does not automatically translate into being the leader of the opposition in the sense that most foreign readers would understand it. “Leader of the opposition” is a very British term. It applies to the Westminster system of parliamentary democracy, and to some extent, to other democracies. If you look at the UK right now, Conservative Party head Kemi Badenoch is
From the Iran war and nuclear weapons to tariffs and artificial intelligence, the agenda for this week’s Beijing summit between US President Donald Trump and Chinese President Xi Jinping (習近平) is packed. Xi would almost certainly bring up Taiwan, if only to demonstrate his inflexibility on the matter. However, no one needs to meet with Xi face-to-face to understand his stance. A visit to the National Museum of China in Beijing — in particular, the “Road to Rejuvenation” exhibition, which chronicles the rise and rule of the Chinese Communist Party — might be even more revealing. Xi took the members
A Pale View of Hills, a movie released last year, follows the story of a Japanese woman from Nagasaki who moved to Britain in the 1950s with her British husband and daughter from a previous marriage. The daughter was born at a time when memories of the US atomic bombing of Nagasaki during World War II and anxiety over the effects of nuclear radiation still haunted the community. It is a reflection on the legacy of the local and national trauma of the bombing that ended the period of Japanese militarism. A central theme of the movie is the need, at
The Chinese Nationalist Party (KMT) and the Taiwan People’s Party (TPP) on Friday used their legislative majority to push their version of a special defense budget bill to fund the purchase of US military equipment, with the combined spending capped at NT$780 billion (US$24.78 billion). The bill, which fell short of the Executive Yuan’s NT$1.25 trillion request, was passed by a 59-0 margin with 48 abstentions in the 113-seat legislature. KMT Chairwoman Cheng Li-wun (鄭麗文), who reportedly met with TPP Chairman Huang Kuo-chang (黃國昌) for a private meeting before holding a joint post-vote news conference, was said to have mobilized her
RSS